Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Change in Accured Expenses (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Change in Accured Expenses for 15 consecutive years, with $126545.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses fell 46.06% year-over-year to $126545.0, compared with a TTM value of -$74767.0 through Sep 2025, down 156.1%, and an annual FY2024 reading of $32799.0, down 94.36% over the prior year.
  • Change in Accured Expenses was $126545.0 for Q3 2025 at BioRestorative Therapies, down from $203315.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $284658.0 in Q4 2021 and bottomed at -$466875.0 in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $67640.8, with a median of $138525.0 recorded in 2024.
  • The sharpest move saw Change in Accured Expenses surged 1626390.0% in 2023, then tumbled 491.19% in 2024.
  • Year by year, Change in Accured Expenses stood at $284658.0 in 2021, then tumbled by 94.58% to $15423.0 in 2022, then surged by 955.14% to $162734.0 in 2023, then tumbled by 61.75% to $62248.0 in 2024, then surged by 103.29% to $126545.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for BRTX at $126545.0 in Q3 2025, $203315.0 in Q2 2025, and -$466875.0 in Q1 2025.